top of page
Data STACK-01.png

Data & Analytics Highlighting Industry Stats, Trends, Analogs, Company Profiles, and Key Insights

Pipeline & Launch Analytics
Legal Analytics
Pricing, Access, Rebate, & Sales Analytics

IPD's Data STACK subscriptions support decision-making with curated datasets and visualizations, expert analytics, easy-to-use analog generators, and trend reports in these impactful coverage areas:

DS Rocket Icon.jpg

Pipeline & Launch Analytics

  • Brand pipeline and launch analytics

    • Clinical development​

    • Brand drug approvals

  • Generic filing and launch analytics

    • Generic pipeline and launches​

    • ANDA filing and timing

    • Authorized generics

    • Generic launch analogs and competitive intelligence

  • Company Profiles

  • Insights and Trend Reports

DS Gavel Icon.jpg

Legal Analytics

  • Litigation filing analytics

  • Settlement analytics

  • Litigation outcome analytics

  • Litigation decision timing analytics

  • Company Profiles

  • Insights and Trend Reports

  • Sales and rebate analytics

  • Therapy cost analytics

  • Hospital price transparency analytics

  • Epidemiology analytics

  • Formulary analytics

  • Limited distribution analytics

  • Company Profiles

  • Insights and Trend Reports

DS Pie Icon.jpg

Pricing, Access, Rebate, & Sales Analytics

Explore Recent Reports

February 2026

January 2026 Drug Price Changes

IPD Analytics has released a new report, “January 2026 Drug Price Changes,” highlighting trends in brand and generic pricing at the start of the year. More than 800 brand drugs and over 50 generic drugs experienced price increases in January 2026.

Read All

December 2025

U.S. Insights: Top 20 Small-Molecule Brand Drugs Facing Generic Competition by Year-End 2026

IPD Analytics has released a new Data STACK Trend Report, “U.S. Insights: Top 20 Small-Molecule Brand Drugs Facing Generic Competition by Year-End 2026.” This report examines the top 20 small-molecule brand drugs, including 13 blockbuster products, that may face first-time generic competition by the end of 2026.

Read All
bottom of page